Challenges with Luteinizing Hormone-Releasing Hormone Agonists: Flare and Surge
Identifieur interne : 003186 ( Pmc/Curation ); précédent : 003185; suivant : 003187Challenges with Luteinizing Hormone-Releasing Hormone Agonists: Flare and Surge
Auteurs : Michael K. BrawerSource :
- Reviews in Urology [ 1523-6161 ] ; 2004.
Abstract
Although the mechanism behind the role of circulating androgens in the development and progression of prostatic carcinoma is not totally clear, androgen deprivation therapy remains a mainstay of treatment for this cancer. As surgical orchiectomy has fallen out of favor and the use of estrogens has been associated with cardiac toxicity, pharmacologic approaches have become even more common, namely, the use of luteinizing hormone-releasing hormone (LHRH) agonists. These agents, however, are not without side effects; the primary ones are the “flare” phenomenon, which stems from an initial surge in testosterone level and can include increased pain at metastatic sites, spinal cord compression, and even sudden death. Some studies have reported increased morbidity with the use of LHRH agonists, and while the significance of flare is not entirely known at this point, data seem to indicate that, at least in men with advanced disease, avoiding flare may be prudent.
Url:
PubMed: 16985931
PubMed Central: 1472887
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003187
Links to Exploration step
PMC:1472887Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Challenges with Luteinizing Hormone-Releasing Hormone Agonists: Flare and Surge</title><author><name sortKey="Brawer, Michael K" sort="Brawer, Michael K" uniqKey="Brawer M" first="Michael K" last="Brawer">Michael K. Brawer</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">16985931</idno><idno type="pmc">1472887</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1472887</idno><idno type="RBID">PMC:1472887</idno><date when="2004">2004</date><idno type="wicri:Area/Pmc/Corpus">003187</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">003187</idno><idno type="wicri:Area/Pmc/Curation">003186</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">003186</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Challenges with Luteinizing Hormone-Releasing Hormone Agonists: Flare and Surge</title><author><name sortKey="Brawer, Michael K" sort="Brawer, Michael K" uniqKey="Brawer M" first="Michael K" last="Brawer">Michael K. Brawer</name></author></analytic><series><title level="j">Reviews in Urology</title><idno type="ISSN">1523-6161</idno><imprint><date when="2004">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Although the mechanism behind the role of circulating androgens in the development and progression of prostatic carcinoma is not totally clear, androgen deprivation therapy remains a mainstay of treatment for this cancer. As surgical orchiectomy has fallen out of favor and the use of estrogens has been associated with cardiac toxicity, pharmacologic approaches have become even more common, namely, the use of luteinizing hormone-releasing hormone (LHRH) agonists. These agents, however, are not without side effects; the primary ones are the “flare” phenomenon, which stems from an initial surge in testosterone level and can include increased pain at metastatic sites, spinal cord compression, and even sudden death. Some studies have reported increased morbidity with the use of LHRH agonists, and while the significance of flare is not entirely known at this point, data seem to indicate that, at least in men with advanced disease, avoiding flare may be prudent.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Rev Urol</journal-id><journal-id journal-id-type="publisher-id">RIU</journal-id><journal-title>Reviews in Urology</journal-title><issn pub-type="ppub">1523-6161</issn><publisher><publisher-name>MedReviews, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16985931</article-id><article-id pub-id-type="pmc">1472887</article-id><article-id pub-id-type="other">1523-6161-6-7-S12</article-id><article-categories><subj-group subj-group-type="heading"><subject>Treatment of Symptomatic Prostate Cancer Patients</subject></subj-group></article-categories><title-group><article-title>Challenges with Luteinizing Hormone-Releasing Hormone Agonists: Flare and Surge</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Brawer</surname><given-names>Michael K</given-names></name><degrees>MD</degrees></contrib><aff><institution>Northwest Prostate Institute, Northwest Hospital</institution><addr-line>Seattle, WA</addr-line></aff></contrib-group><pub-date pub-type="ppub"><year>2004</year></pub-date><volume>6</volume><issue>Suppl 7</issue><fpage>S12</fpage><lpage>S18</lpage><permissions><copyright-statement>© 2004 MedReviews, LLC</copyright-statement><copyright-year>2004</copyright-year><copyright-holder>MedReviews, LLC</copyright-holder></permissions><abstract><p>Although the mechanism behind the role of circulating androgens in the development and progression of prostatic carcinoma is not totally clear, androgen deprivation therapy remains a mainstay of treatment for this cancer. As surgical orchiectomy has fallen out of favor and the use of estrogens has been associated with cardiac toxicity, pharmacologic approaches have become even more common, namely, the use of luteinizing hormone-releasing hormone (LHRH) agonists. These agents, however, are not without side effects; the primary ones are the “flare” phenomenon, which stems from an initial surge in testosterone level and can include increased pain at metastatic sites, spinal cord compression, and even sudden death. Some studies have reported increased morbidity with the use of LHRH agonists, and while the significance of flare is not entirely known at this point, data seem to indicate that, at least in men with advanced disease, avoiding flare may be prudent.</p></abstract><kwd-group><title>Key words</title><kwd>Dihydrotestosterone</kwd><kwd>Luteinizing hormone-releasing hormone</kwd><kwd>Flare</kwd><kwd>Prostatic carcinoma</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003186 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 003186 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:1472887
|texte= Challenges with Luteinizing Hormone-Releasing Hormone Agonists: Flare and Surge
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:16985931" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |